文献速递临床试验与 GCP基础与转化研究

基于(1,3)-β-D-葡聚糖诊断侵袭性念珠菌感染与培养诊断在脓毒症及高风险患者中的比较(CandiSep):随机对照试验研究方案

(1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2018-09-04

CandiSep是一项在德国19个ICU开展的前瞻性多中心开放随机对照试验,计划纳入312例严重脓毒症或脓毒性休克且具有侵袭性念珠菌感染(ICI)高危因素的成人患者,随机分为BDG指导抗真菌治疗组与标准治疗组,主要结局为28天死亡率,旨在评估BDG检测能否缩短经验性抗真菌治疗时间并提高生存率。

要点

  • 脓毒症合并ICI高危因素患者随机接受BDG指导或标准治疗。
  • BDG组至少一次样本≥80 pg/ml即启动抗真菌治疗。
  • 主要结局为28天死亡率,计划纳入312例。

核心结论

  • 该研究旨在明确脓毒症合并ICI高危患者中BDG检测能否缩短经验性抗真菌治疗时间并提高生存率。

研究设计与样本

  • 前瞻性多中心开放随机对照试验,在德国19个重症监护病房开展,计划纳入312例严重脓毒症或脓毒性休克且具有ICI高危因素的成人患者。
  • 高危因素包括全肠外营养、既往腹部手术、既往抗菌治疗和肾脏替代治疗。
  • 排除已确诊ICI或已接受全身抗真菌治疗的患者,按意向治疗原则分析。

主要发现

  • 原文未报告研究结果,仅报告研究方案。

关键数值与推荐

  • BDG组在随机化后及24小时后采集血清BDG样本,至少一次样本BDG≥80 pg/ml时启动抗真菌治疗。
  • 标准治疗组按需接受目标性抗真菌治疗。
  • 主要结局为28天死亡率,其他结局包括28天内无抗真菌生存、至抗真菌治疗时间及BDG与其他实验室检查对早期ICI诊断的诊断性能。

临床怎么用

  • 美国指南推荐对ICI高危脓毒症患者经验性抗真菌治疗,欧洲指南不推荐,BDG可能识别需要早期抗真菌治疗的患者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The time to diagnosis of invasive Candida infection (ICI) is often too long to initiate timely antifungal therapy in patients with sepsis. Elevated serum (1,3)-β-D-glucan (BDG) concentrations have a high diagnostic sensitivity for detecting ICI. However, the clinical significance of elevated BDG concentrations is unclear in critically ill patients. The goal of this study is to investigate whether measurement of BDG in patients with sepsis and a high risk for ICI can be used to decrease the time to empiric antifungal therapy and thus, increase survival. METHODS/DESIGN: This prospective multicenter open randomized controlled trial is being conducted in 19 German intensive care units. All adult patients with severe sepsis or septic shock and an increased risk for ICI are eligible for enrolment. Risk factors are total parenteral nutrition, previous abdominal surgery, previous antimicrobial therapy, and renal replacement therapy. Patients with proven ICI or those already treated with systemic antifungal substances are excluded. Patients are allocated to a BDG or standard care group. The standard care group receives targeted antifungal therapy as necessary. In the BDG group, BDG serum samples are taken after randomization and 24 h later. Antifungal therapy is initiated if BDG is ≥80 pg/ml in at least one sample. We plan to enroll 312 patients. The primary outcome is 28-day mortality. Other outcomes include antifungal-free survival within 28 days after enrolment, time to antifungal therapy, and the diagnostic performance of BDG compared to other laboratory tests for early ICI diagnosis. The statistical analysis will be performed according to the intent-to-treat principle. DISCUSSION: Because of the high risk of death, American guidelines recommend empiric antifungal therapy in sepsis patients with a high risk of ICI despite the limited evidence for such a recommendation. In contrast, empiric antifungal therapy is not recommended by European guidelines. BDG may offer a way out of this dilemma since BDG potentially identifies patients in need of early antifungals. However, the evidence for such an approach is inconclusive. This clinical study will generate solid evidence for health-care providers and authors of guidelines for the use of BDG in critically ill patients. TRIAL REGISTRATION: Clinicaltrials.gov, NCT02734550 . Registered 12 April 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bloos F, Held J, Schlattmann P, et al. (1,3)-β-D-glucan-based diagnosis of invasive Candida infection versus culture-based diagnosis in patients with sepsis and with an increased risk of invasive Candida infection (CandiSep): study protocol for a randomized controlled trial. Trials. 2018. PMID: 30180873. doi:10.1186/s13063-018-2868-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。